A business joint venture (BV) comprising Teva Pharmaceutical and Takeda Pharmaceutical in Japan is set to divest the majority of its generic and operational assets to Nichi-Iko Pharmaceutical.
Israeli drugmaker Teva and Japan's Takeda have undergone separate, yearslong cutback sprees, looking to slice away a range of underperforming assets. Now, the two drugmakers will take a scalpel to their joint venture in Japan as they continue to hunt for savings.
Chugai Pharmaceutical Co., Ltd. announced today that it has filed a patent infringement lawsuit with the Tokyo District Court and has also filed a petition for provisional disposition order, demanding the suspension of manufacturing and distribution of the generic drugs of an osteoporosis agent, active vitamin D3 derivative Edirol® Capsule 0.5µg / 0.75µg (generic name: eldecalcitol, hereafter, Edirol Capsule), against Sawai Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd., the marketing authorization holders of generic versions of the drug, citing such parties’ infringement of a use patent owned by Chugai and Taisho Pharmaceutical Co., Ltd.
A blood thinner used to treat pancreatitis and kidney disease has been identified as a potential therapy for coronavirus patients, with clinical trials in Japan possibly set to begin within a month, researchers at the University of Tokyo said Wednesday.
Japanese makers of generic drugs, the cheaper alternatives to name-brand pharmaceuticals, are learning that their relentless efforts to keep prices down come at a cost -- their reliance on chemical ingredients, or drug precursors, from China is opening them up to supply disruption.
Catalent has invested $9 million in a clinical supply facility and Sagent has access to expanded manufacturing in Canada from its parent.
Japan’s Nichi-Iko Pharmaceutical bought Illinois-based Sagent Pharmaceuticals in 2016 to get a foothold in the U.S. Now Nichi-Iko is establishing a solid U.S. manufacturing footprint by acquiring a plant in North Carolina.
Mumbai based Lupin pharma and Japan's
Pharma major Lupin and Nichi-Iko announced that the two companies have entered into an agreement for the distribution, promotion and sale of Lupin’s recently-filed biosimilar Etanercept (YLB113) in Japan.